You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Effect of VBP15, a dissociative steroidal analogue, on intestinal epithelial repair processes in inflammatory bowel disease
SBC: REVERAGEN BIOPHARMA, INC. Topic: NIDDK? DESCRIPTION (provided by applicant): Glucocorticoids (e.g. prednisolone) are prescribed frequently to treat inflammatory bowel disease (IBD). Despite effectiveness, adverse side effects believed to be caused by GRE-mediated transcriptional propertieslimit long term use of glucocorticoids in IBD patients. Furthermore, these GRE-mediated transcriptional activities have been previously shown to ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing a Nrf2 activator for the treatment of COPD
SBC: CUREVEDA, LLC Topic: NHLBIDESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity worldwide. In the US alone, the disease afflicts ~13 million people and is the third-leading cause of death. Cigarette smoking isthe primary risk factor for COPD, initiating a persistent and progressive inflammatory immune response. Respiratory infections and pollutants can ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of VBP15 a dissociative steroidal analogue on pain and inflammation
SBC: REVERAGEN BIOPHARMA, INC. Topic: NIMHDDESCRIPTION (provided by applicant): The treatment of pain in Sickle Cell Disease (SCD) is challenging for both patients and providers and is associated with significant disparities in healt care delivery. While the role of ongoing inflammation during vasooclusive crisis and pain is recognized, effective therapeutic interventions are lacking. Glucocorticoids, with their anti-inflammatory propertie ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
